Trial of Prasinezumab in Early-Stage Parkinson’s Disease-Reference-Cited by-同舟云学术

Trial of Prasinezumab in Early-Stage Parkinson’s Disease

Published:2022-08-04 Issue:5 Volume:387 Page:421-432
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Pagano Gennaro¹,Taylor Kirsten I.¹,Anzures-Cabrera Judith¹,Marchesi Maddalena¹,Simuni Tanya¹,Marek Kenneth¹,Postuma Ronald B.¹,Pavese Nicola¹,Stocchi Fabrizio¹,Azulay Jean-Philippe¹,Mollenhauer Brit¹,López-Manzanares Lydia¹,Russell David S.¹,Boyd James T.¹,Nicholas Anthony P.¹,Luquin María R.¹,Hauser Robert A.¹,Gasser Thomas¹,Poewe Werner¹,Ricci Benedicte¹,Boulay Anne¹,Vogt Annamarie¹,Boess Frank G.¹,Dukart Juergen¹,D’Urso Giulia¹,Finch Rebecca¹,Zanigni Stefano¹,Monnet Annabelle¹,Pross Nathalie¹,Hahn Andrea¹,Svoboda Hanno¹,Britschgi Markus¹,Lipsmeier Florian¹,Volkova-Volkmar Ekaterina¹,Lindemann Michael¹,Dziadek Sebastian¹,Holiga Štefan¹,Rukina Daria¹,Kustermann Thomas¹,Kerchner Geoffrey A.¹,Fontoura Paulo¹,Umbricht Daniel¹,Doody Rachelle¹,Nikolcheva Tania¹,Bonni Azad¹

Affiliation:

1. From the Neuroscience and Rare Diseases, Discovery and Translational Area (G.P., K.I.T., A. Boulay, A.V., F.G.B., J.D., G.D., H.S., M.B., S.D., Š.H., T.K., G.A.K., D.U., A. Bonni), and Pharmaceutical Sciences (B.R.), Roche Pharma Research and Early Development (pRED), and Roche pRED Informatics (F.L., E.V.-V., M.L.), Roche Innovation Center Basel, and Product Development Neuroscience (S.Z., A.M., N. Pross, P.F., R.D., T.N.) and Product Development Safety (M.M., D.R.), F. Hoffmann–La Roche — all in Basel,...

Funder

F. Hoffmann-La Roche

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2202867

Reference16 articles.

1. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations

2. Nucleic Acid–Based Therapeutics for Parkinson’s Disease

3. -Synuclein in Parkinson's Disease